i-Fect Protocol for Intrathecal Administration of siRNA
Protocol developed in collaboration with Miaw-Chyi Luo, Ph.D. and Josephine Lai, PhD, University of Arizona.
Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, Porreca F, Lai J. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain. 2005 Sep 28; 1:29.
To date, we have tested exclusively siRNA and control RNA that are synthesized initially as 2 separate complementary strands by solid phase synthesis, de-protected and RNase-free HPLC purified. The RNA preparations are reconstituted separately to a concentration of 200 Î¼M in annealing buffer as described (Elbashir et al, 2001). RNA duplexes are formed by mixing equal volume of the RNA solutions for 3 min at 90Â°C followed by 60 min at 37Â°C to yield a final concentration of 100 Î¼M double stranded RNA. The RNA
duplexes are aliquoted (typically in 20Î¼L) and stored in â€“80Â°C. Always avoid repeated freezing and thawing of the samples.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-8.
Catheter implantation for the intrathecal delivery of siRNA into rats
The surgical procedure for intrathecal catheter implantation that we have exclusively employed is that described by Yaksh and Rudy (1976).
The catheter is directed to the lumbar region of the spinal cord and the external opening should be heat-sealed until use. It is highly recommended that the experimental animals should be allowed to recover for 5 to 7 days post-surgery before any further experimental manipulations. It is also critical that the patency of the catheters is verified prior to experiment. Patency of the catheters declines over time, thus optimally siRNA administration should begin soon after the allotted recovery time stated above.
Yaksh TL, Rudy TA (1976) Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1031-6.
Preparation of siRNA for intrathecal administration
On the day of the injection, thaw an aliquot(s) of the siRNA and control RNA ON ICE. At the same time, warm the desired quantity of i-Fect to room temperature.
IMPORTANT: The i-Fect is used undiluted without the addition of the siRNA diluent.
To inject a 2 Î¼g (for a 21 mer, this is equivalent to 0.14 nmol) dose of siRNA or control RNA per rat for a group size of 6 rats, mix 12 Î¼L of the 100 Î¼M RNA stock with 60 Î¼L of i-Fect (1:5 v/v). This is equivalent to 15 Î¼g of RNA in 60 Î¼L of i-Fect (1:4 w/v) to yield a total volume of 72 Î¼L of RNA/i-Fect solution.
Mix the RNA and i-Fect by GENTLY swirling the solution with a sterile pipet tip and allow the mixture to stand for 5 min at room temperature.
IMPORTANT: Add the siRNA to the i-Fect reagent to avoid siRNA precipitate. If i-Fect is added to siRNA solution, precipitation has been observed.
At this 1:4 w/v ratio, the RNA should remain soluble in the transfection reagent; the mixture should be clear to slightly cloudy. More RNA or less volume of i-Fect will cause the RNA to precipitate out of solution and is not recommended.
Intrathecal administration of siRNA
It is highly recommended that the RNA/i-Fect solution be injected WITHIN 30 MINUTES after it is prepared. For intrathecal injection, draw 9 Î¼L of sterile saline solution into a Hamilton syringe, followed by 1 Î¼L of air, and 10 Î¼L of the RNA/i-Fect solution. Inject the content slowly into the catheter, noting the air bubbleâ€™s movement and that it does not show any compression. We routinely include a vehicle control group, for which each rat receives 10 Î¼L of i-Fect. It should be noted that the volume of intrathecal delivery is typically between 5 Î¼L and 10 Î¼L, and so the 2 Î¼g RNA used in this protocol represents the maximum bolus dose of RNA in i-Fect that can be delivered intrathecally. Treatment of up to 6 doses of either i-Fect or this dose of RNA/i-Fect solution over a period of 72 hours did not precipitate any overt sign of behavioral toxicity.
FOR RESEARCH USE ONLY v3
Neuromicsâ€™ reagents are for in vitro and certain non-human in vivo experimental use only and not intended for use in any human clinical investigation, diagnosis, prognosis, or treatment. We disclaim all liability in connection with the use of the information contained herein or otherwise, and all such risks are assumed by the user.